Skip to main content

Animations

MJFF Publications

2081 - 2090 of 8399 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: A late-onset neurological disorder: is progression inevitable?
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.014
    Best OA location URL:
    Citation Count: 0
  • OPEN
    Title: Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.019
    Best OA location URL:
    Citation Count: 1
  • OPEN
    Title: Telemedicine as an Untapped Opportunity for Parkinson’s Nurses Training in Personalized Care Approaches
    Journal Name: Journal of Personalized Medicine
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/jpm12071057
    Citation Count: 3
  • OPEN
    Title: Aromaticity at position 39 in α‐synuclein: A modulator of amyloid fibril assembly and membrane‐bound conformations
    Journal Name: Protein Science
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/pro.4360
    Citation Count: 9
  • RESTRICTED
    Title: Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1601
    Best OA location URL:
    Citation Count: 0
  • RESTRICTED
    Title: Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1604
    Best OA location URL:
    Citation Count: 0
  • OPEN
    Title: Dopamine transporter single-photon emission computed tomography-derived radiomics signature for detecting Parkinson’s disease
    Journal Name: EJNMMI Research
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13550-022-00910-1
    Citation Count: 9
  • RESTRICTED
    Title: Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Journal Name: Pharmacological Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s43440-022-00378-9
    Best OA location URL:
    Citation Count: 5
  • OPEN
    Title: Genetic prediction of impulse control disorders in Parkinson's disease
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/acn3.51569
    Citation Count: 28
  • OPEN
    Title: Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson’s disease: correlation with postural and gait deficits
    Journal Name: Journal of Neural Transmission
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00702-022-02523-3
    Citation Count: 14
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.